Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias

2024-9-9

Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care

2024-9-7

A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist

2024-9-3

Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study

2024-9-2

MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation—A Tutorial

2024-8-29

Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: An Updated Systematic Literature Review

2024-8-24

Bring Out Your Dead: A Review of the Cost Minimisation Approach in Health Technology Assessment Submissions to the Australian Pharmaceutical Benefits Advisory Committee

2024-8-24

Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling

2024-8-23

Drug Pricing Stewardship from Mark Cuban’s Cost Plus Generic Drug Program

2024-8-21

Considerations Around the Inclusion of Children and Young People’s Time in Economic Evaluation: Findings from an International Delphi Study

2024-8-17

Using Cure Modelling for Cost Effectiveness in the NICE Technology Appraisal of Polatuzumab Vedotin in Combination for Untreated Diffuse Large B Cell Lymphoma: An External Assessment Group Perspective

2024-8-9

Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses

2024-8-7

Improving Transparency of Decision Models Through the Application of Decision Analytic Models with Omitted Objects Displayed (DAMWOOD)

2024-8-7

Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling

2024-8-6

Delaying Oral Anticoagulants: A False Economy?

2024-8-2

Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications

2024-8-2

Delay and Pay? Healthcare Costs Associated with Late Oral Anti-coagulant Prescribing in People with Atrial Fibrillation

2024-8-2

Unravelling Elements of Value of Healthcare and Assessing their Importance Using Evidence from Two Discrete-Choice Experiments in England

2024-7-31

Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer

2024-7-26

Proxy Preferences and the Values of Children’s Health States

2024-7-22

Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know

2024-7-5

Measuring the Direct Medical Costs of Hospital-Onset Infections Using an Analogy Costing Framework

2024-7-5

Evaluating the Public Health and Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for Influenza Pandemic Control in China: A Cost-Effectiveness Analysis Using a Linked Dynamic Transmission–Economic Evaluation Model

2024-7-3

Cost-Effectiveness of Plasma Microbial Cell-Free DNA Sequencing When Added to Usual Care Diagnostic Testing for Immunocompromised Host Pneumonia

2024-7-2

Estimating an EQ-5D-Y-3L Value Set for Brazil

2024-7-2

Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management

2024-6-26

A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models

2024-6-25

Advancing Methods to Measure and Reward Healthcare Innovation

2024-6-24

Evaluating the Cost-Utility of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Systematic Review of the Methods and Quality of Studies Using Decision Models or Empirical Data

2024-6-21

Rapid Assessment of the Need for Evidence: Applying the Principles of Value of Information to Research Prioritisation

2024-6-20

PharmacoEconomics Supplement

2024-6-15

Correction to: Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists’ and Urologists’ Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries

2024-6-14

A Systematic Review of Methods for Estimating Productivity Losses due to Illness or Caregiving in Low- and Middle-Income Countries

2024-6-14

NICE Approaches to Expert Opinion Evidence in Highly Specialised Technologies: Time to Change? Evidence Assessment Group Perspective

2024-6-11

A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies

2024-5-31

A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses

2024-5-31

The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment

2024-5-31

Comparing Generic Paediatric Health-Related Quality-of-Life Instruments: A Dimensionality Assessment Using Factor Analysis

2024-5-31

Examining the Effect of Depicting a Patient Affected by a Negative Reimbursement Decision in Healthcare on Public Disagreement with the Decision

2024-5-26

Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective

2024-5-21

Bayesian Meta-Analysis of Health State Utility Values: A Tutorial with a Practical Application in Heart Failure

2024-5-20

A Prototype Software Framework for Transferable Computational Health Economic Models and Its Early Application in Youth Mental Health

2024-5-20

Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework

2024-5-17

Cost-of-Illness of Skin Cancer: A Systematic Review

2024-5-16

A Comparison of the Psychometric Properties of the EQ-5D-Y-3L and EQ-5D-Y-5L Using Paediatric Multi-Instrument Comparison (P-MIC) Study Data

2024-5-15

Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs?

2024-5-11

Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review

2024-5-10

PharmacoEconomics Supplement

2024-5-9

Market Transparency in Medicine Pricing: Pathways to Fair Pricing

2024-5-9

Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children

2024-5-9